OncoAlert 4Sight 摘要将在 #ESMO26 上展示
FLAURA2：接受一线奥希替尼 ± 铂类–培美曲塞治疗的 EGFR 突变晚期 NSCLC 患者治疗期间血浆 EGFRm 动态及相关临床结局分析
@dplanchard
🫁 FLAURA2 III 期探索性 ctDNA 分析：一线奥希替尼 ± 铂类–培美曲塞治疗 EGFRm 晚期 NSCLC 患者第 1、2、3、6 周血浆 EGFRm 清除（ddPCR）。
➡️ 第 6 周清除率：88% 对 89%
➡️ 第 6 周已清除：PFS HR 0.52 (0.36–0.76)；未清除：PFS HR 0.40 (0.16–0.97)
➡️ 第 6 周 OS HR 0.73（已清除）和 0.50（未清除）
✅ 清除具有预后意义但无预测意义；无论清除状态如何，奥希替尼 + 铂类–培美曲塞均优于单用奥希替尼。 #NSCLC
🎙️ David Planchard
👥 Pasi Jänne · Ying Cheng · James Yang · Noriko Yanagitani · Sang-We Kim · Shunichi Sugawara · Yan Yu · Yun Fan · Sarayut Geater · Konstantin Laktionov · Chee Lee · Natalia Valdiviezo · Samreen Ahmed · Jean-Marc Maurel · Igor Andrasina · Jonathan Goldman · Dana Ghiorghiu · Yuri Rukazenkov · Alex Todd · Kunihiko Kobayashi
（4Sight 基于 ESMO 网站公开的摘要制作）
致相关专家
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
231 浏览 · 1 赞 · 1 转发 · 1 回复
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org- Dr. Robert@robt_heartdoc
@OncoAlert @dplanchard Agree. Teachable moment for the ctDNA field. Clearance was prognostic, not predictive, so the combination benefit holds regardless. ddPCR is single-marker; the planned multi-marker studies will be the real test. Kudos for the honest framing.
来源：OncoAlert · x.com